PW Medtech GroupFRA:PWE 82 EBITDA Margin % is 15.22% as of Dec. 2025, which is 68% below its 10-year median of 47.03. GuruFocus rates FRA:PWE with a GF Score™ of 82/100 and a GF Value™ of €0.13. The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, PW Medtech Group ranks better than 75.49% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PW Medtech Group's EBITDA for the
six
months ended in Dec. 2025 was €7.55 Mil. PW Medtech Group's Revenue for the
six
months ended in Dec. 2025 was €49.61 Mil. Therefore, PW Medtech Group's EBITDA margin for the quarter that ended in Dec. 2025 was 15.22%.
PW Medtech Group (FRA:PWE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PW Medtech Group EBITDA Margin % Related Terms
PW Medtech Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PW Medtech Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PWE vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, PW Medtech Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PW Medtech Group (FRA:PWE) has a EBITDA Margin % of 15.22% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PW Medtech Group and its competitors. This is 68% below median its historical median of 47.03. Over the past decade, PW Medtech Group's EBITDA Margin % has ranged from 20.10 to 283.53. According to the industry distribution chart, PW Medtech Group ranks #200 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 24.5%.
Is PW Medtech Group's EBITDA Margin % too high?
PW Medtech Group's current EBITDA Margin % of 15.22% is 68% below median its 10-year median of 47.03. Over the past 10 years, this metric has ranged from a low of 20.10 to a high of 283.53. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. PW Medtech Group's value of 15.22% is 103.6% above this industry median. Based on the distribution chart, PW Medtech Group ranks #200 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PW Medtech Group has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PW Medtech Group ranks #200 out of 816 companies for EBITDA Margin %. This places PW Medtech Group in the top 25% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. PW Medtech Group's value of 15.22% is 103.6% above this benchmark. Historically, PW Medtech Group's own EBITDA Margin % has ranged from 20.10 to 283.53 over the past decade. While the company's 10-year median is 47.03 vs. the industry median of 7.48, PW Medtech Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PW Medtech Group's current EBITDA Margin % of 15.22% is 103.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PW Medtech Group and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PW Medtech Group's current EBITDA Margin % is 15.22%, which is 68% below median its own 10-year median of 47.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
PW Medtech Group (FRA:PWE) has a current EBITDA Margin % of 15.22%. The stock's GF Value™ is €0.13, compared to a current price of €0.11 — trading 15.4% below its estimated fair value. The current EBITDA Margin % is 15.22%, which is 68% below median its 10-year median of 47.03 and 103.6% above the Medical Devices & Instruments industry median of 7.48. PW Medtech Group's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current EBITDA Margin % is 15.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PW Medtech Group (FRA:PWE) Overvalued in 2026?
Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued.
The current stock price of €0.11 is trading 15.4% below its estimated GF Value™ of €0.13.
Key valuation signals for FRA:PWE:
EBITDA Margin %: 15.22% (68% below median its 10-year median of 47.03)
GF Value™: €0.13 vs. price of €0.11 (15.4% below fair value)
Industry Position: 103.6% above the Medical Devices & Instruments median (#200 of 816)
No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
82GF Score
Get the complete analysis for FRA:PWE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PWE has been successfully added to your 
